Skip to content

COVID Antibodies Wane Against New Variants, Study Finds

Antibodies from early COVID-19 variants may not protect against newer ones. Vaccination remains crucial in the face of evolving strains.

In this image we can see few people standing and a person is holding a vaccine bottle and there is...
In this image we can see few people standing and a person is holding a vaccine bottle and there is a calendar and text on the image.

COVID Antibodies Wane Against New Variants, Study Finds

Australian scientists have published a comprehensive study in PLOS Medicine (DOI: 10.1371/journal.pmed.1003656) revealing the reduced effectiveness of antibodies produced against early COVID-19 variants against contemporary ones. The research, a collaboration between the University of Sydney, Kids Research, Sydney Children's Hospitals Network, the Kirby Institute at UNSW Sydney, Australian Red Cross Lifeblood, St Vincent's Hospital, NSW Health Pathology, and other local and international partners, analyzed the serum of 233 COVID-19 patients over seven months.

The study found that the level of immunity over time is dependent on the severity of the disease and the viral variant. Antibodies developed during the first wave had reduced effectiveness against six variants, including those from the second wave in Australia and three variants of concern globally. Notably, a rare group of 'super responders' maintained a stable and robust level of antibodies across all COVID-19 variants.

The research highlights the importance of continued vaccine development to keep pace with emerging COVID variants. It also underscores that vaccination is more effective than the body's natural immune response following infection against emerging COVID variants. The study is one of the world's most comprehensive on the immune response against COVID-19 infection.

The study, led by Australian scientists, underscores the need for ongoing vaccine updates to combat the evolving COVID-19 landscape. While natural immunity may wane over time and vary in effectiveness against different variants, vaccination remains a robust defense against emerging COVID variants. The research also sheds light on the immune response of 'super responders', offering potential avenues for future study.

Read also:

Latest